Table 6

 Univariate disease related and recurrence-free survival analyses of the patients

VariableSurviving at 10 yearsRecurrence-free at 10 years
n (%)p Value*n (%)p Value*
*Log-rank analysis.
FIGO, International Federation of Gynecologists and Obstetricians.
Age (years)2950.0041610.15
    <5062 (52%)38 (66%)
    50–65127 (35%)71 (48%)
    >65106 (29%)52 (52%)
Histological grade295<0.0011610.12
    144 (52%)29 (66%)
    2103 (45%)61 (57%)
    3148 (26%)71 (45%)
Histological type2950.0481610.006
    Serous106 (28%)52 (35%)
    Mucinous33 (58%)26 (69%)
    Endometrioid78 (37%)38 (63%)
    Clear cell31 (48%)22 (64%)
    Miscellaneous47 (30%)23 (52%)
FIGO stage295<<0.001161<0.001
    I83 (72%)73 (67%)
    II47 (43%)34 (56%)
    III135 (18%)49 (33%)
    IV30 (10%)5 (40%)
Primary residual tumour271<<0.001153<0.001
    None121 (68%)103 (66%)
    ⩽2 cm51 (20%)29 (34%)
    >2 cm99 (12%)21 (24%)
Adjuvant chemotherapy2920.111600.23
    Platin based161 (30%)79 (48%)
    Non-platin97 (41%)58 (57%)
    None34 (50%)23 (65%)
E-Cadherin in cancer cells (strong continuous)2730.121490.038
    ⩽5%198 (33%)106 (46%)
    >5%75 (43%)43 (67%)
β-Catenin in cancer cells (strong continuous)2860.0351540.033
    ⩽5%219 (31%)115 (48%)
    >5%67 (51%)39 (67%)
γ-Catenin in cancer cells (strong continuous)2830.461500.053
    ⩽5%210 (34%)110 (47%)
    >5%73 (40%)40 (65%)